Amgen Inc. $AMGN Shares Purchased by Ascent Wealth Partners LLC

Key Points

• Ascent Wealth Partners LLC boosted its Amgen stake by 50.8%, buying 4,205 shares to hold 12,480 shares worth $4.085M, and institutional investors now own about 76.5% of the company.
• Amgen beat Q1 expectations with $5.15 EPS and $8.62B revenue (up 5.8% YoY) and set FY‑2026 guidance of $21.70–$23.10 EPS, roughly in line with analyst consensus.
• The company declared a quarterly dividend of $2.52 per share (3.1% yield), while analyst opinions are mixed (consensus "Hold", target ~$357.5) and regulatory risk remains after the FDA proposed withdrawing approval for Tavneos.

Ascent Wealth Partners LLC raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 50.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 12,480 shares of the medical research company's stock after purchasing an additional 4,205 shares during the quarter. Ascent Wealth Partners LLC's holdings in Amgen were worth $4,085,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of AMGN. Vanguard Group Inc. lifted its holdings in Amgen by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company's stock worth $17,949,296,000 after buying an additional 961,975 shares during the last quarter. Capital International Investors lifted its holdings in Amgen by 1.5% during the 3rd quarter. Capital International Investors now owns 19,192,995 shares of the medical research company's stock worth $5,414,296,000 after buying an additional 282,219 shares during the last quarter. Capital World Investors lifted its holdings in Amgen by 11.5% during the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company's stock worth $5,303,578,000 after buying an additional 1,935,876 shares during the last quarter. Capital Research Global Investors lifted its holdings in Amgen by 2.7% during the 3rd quarter. Capital Research Global Investors now owns 4,731,290 shares of the medical research company's stock worth $1,335,168,000 after buying an additional 122,631 shares during the last quarter. Finally, Invesco Ltd. lifted its holdings in Amgen by 6.6% during the 3rd quarter. Invesco Ltd. now owns 4,467,287 shares of the medical research company's stock worth $1,260,668,000 after buying an additional 277,031 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.

Amgen Price Performance

Shares of AMGN stock opened at $329.82 on Monday. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $391.29. The stock has a market cap of $178.00 billion, a PE ratio of 22.95, a price-to-earnings-growth ratio of 3.24 and a beta of 0.44. The business's fifty day moving average is $358.07 and its 200-day moving average is $341.12. The company has a debt-to-equity ratio of 5.65, a quick ratio of 0.90 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company had revenue of $8.62 billion for the quarter, compared to analysts' expectations of $8.58 billion. During the same period last year, the firm earned $4.90 EPS. The firm's revenue for the quarter was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities analysts expect that Amgen Inc. will post 22.28 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 3.1%. Amgen's dividend payout ratio (DPR) is 70.84%.

Analyst Ratings Changes

A number of research analysts have commented on the company. Morgan Stanley set a $332.00 target price on Amgen in a report on Friday. TD Cowen reissued a "buy" rating on shares of Amgen in a report on Wednesday, February 4th. Daiwa Securities Group raised their price target on Amgen from $370.00 to $410.00 and gave the stock an "outperform" rating in a report on Tuesday, February 10th. Citigroup raised their price target on Amgen from $315.00 to $345.00 and gave the stock a "neutral" rating in a report on Wednesday, February 4th. Finally, Deutsche Bank Aktiengesellschaft raised their price target on Amgen from $285.00 to $295.00 and gave the stock a "hold" rating in a report on Thursday, February 5th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $357.54.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q1 results beat expectations — AMGN reported $5.15 EPS vs. $4.73 consensus and product sales rose ~4%, with 16 drugs delivering double‑digit growth, supporting the company’s growth story. Amgen's Q1 Earnings Top Estimates
• Positive Sentiment: Bullish analyst action — Goldman Sachs reiterated a Buy and lifted its price target to $425, signaling long‑term upside from execution and pipeline momentum. Goldman Sachs Raises PT to $425
• Positive Sentiment: Other supportive analyst notes — Some firms (e.g., William Blair) reiterated Buy ratings after the quarter, highlighting confidence in the MariTide/weight‑loss program and execution. Analyst Reiterates Buy
• Neutral Sentiment: Guidance set but roughly in line — Amgen updated FY‑2026 EPS guidance to $21.70–$23.10 (consensus ~22.29), which many read as broadly in‑line rather than materially bullish. Amgen FY2026 Guidance (press release/slide)
• Neutral Sentiment: Small, mixed analyst target moves — Truist nudged its target to $327 with a Hold rating (minimal change), leaving some investors watching for clearer directional signals. Truist Raises PT to $327
• Negative Sentiment: FDA action risk — The FDA proposed withdrawing Tavneos approval after alleging clinical‑trial data issues, raising regulatory, compliance and reputational concerns that can pressure the stock. FDA Tavneos Proposal Coverage
• Negative Sentiment: Investor apprehension over strategy/timing — Some market commentary framed the quarter as “generally in‑line” and expressed concern about Amgen’s aggressive push into obesity (MariTide) and the near‑term profit impact, contributing to selling pressure. Investor Reaction to MariTide Expansion

Amgen Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.